PPAR马和PGC-1α激活剂通过抑制炎症和NF-kappaB激活来保护糖尿病病
Siyi Huang1,2, Yuanmeng Jin1,2, Liwen Zhang3
1Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
过氧体增殖器激活受体 (PPARγ) 和其协同激活器PPARγ协同激活器-1α (PGC-1α) 保护脏炎症. 这些蛋白调节NF-κB通路,为脏疾病提供潜在的治疗点.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 分子生物学分子生物学
- 细胞的新陈代谢
背景情况:
- 炎症是糖尿病病进展的关键驱动因素.
- 已知氧酶增殖器激活受体玛 (PPARγ) 和其协同激活器PPARγ协同激活器-1α (PGC-1α) 抑制炎症并增强细胞能量代谢.
- 在炎中PPARγ和PGC-1α的精确合作机制仍需要阐明.
研究的目的:
- 在炎的背景下研究PPARγ和PGC-1α合作的分子机制.
- 确定PPARγ和PGC-1α在调节细胞内的炎症通路以及糖尿病病模型中的作用.
主要方法:
- 使用HK-2人类近道管状细胞,刺激炎症因子 (TNF-α,IL-1β) 和高葡萄糖.
- 使用RT-qPCR和西部斑点测试评估PPARγ,PGC-1α,p-p65和p65的表达水平.
- 采用糖尿病病小鼠模型 (db/db) 用PPARγ和PGC-1α激活剂治疗,评估损伤和炎症标志物.
主要成果:
- 在体外,炎症性细胞因子 (TNF-α,IL-1β) 降低了PPARγ和PGC-1α的表达和DNA结合能力.
- 通过炎症刺激,NF-κB通路被迅速激活.
- PPARγ和PGC-1α激活剂在细胞和动物模型中表现出对糖尿病病的保护作用,并抑制了NF-κB激活.
结论:
- PPARγ和PGC-1α在减轻脏炎症方面发挥着重要作用.
- 通过PPARγ和PGC-1α调节NF-κB通路是它们保护作用的关键机制.
- 这些发现突出了PPARγ和PGC-1α作为炎症性脏疾病的有前途的治疗点.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
10:37Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
相关概念视频
Cell Specific Gene Expression
GPCRs Regulate Adenylyl Cylase Activity
Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
cAMP-dependent Protein Kinase Pathways
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
